well funded. The one big difference is the financial weakness of universities. The lack of centrally administered resources makes it much harder for universities in the UK to foster new interdisciplinary research areas, and often forces labs to do almost everything for themselves, which can result in considerable inefficiencies. For biomedical research in the UK to remain competitive, the financial health of the major research universities will need to be restored, somehow. 
What do you think is the biggest challenge facing your field? The big applied challenge in my area of human genetics is learning how to incorporate genetic information into healthcare, both at the level of genetically personalized healthcare and in the earlier stages of personalized lifestyle choices. In human evolution, the next major phase will be identifying the genetic bases of the traits that have been under selection in our evolutionary history. And, closing the circle, I am convinced many of these traits will prove to be of medical relevance, especially in terms of how people respond to drugs. Is there anything we don't know? The mechanism of action of many heterochronic genes remains to be determined. For example, lin-14 encodes a novel nuclear protein with no identified downstream effectors to date. In addition, emerging evidence of phylogenetic conservation of heterochronic genes leads to the prospect that mechanisms to control developmental timing will be elucidated in other systems.
Where can I find out more?
